Infant Bacterial Therapeutics AB is a pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. It products include IBP-9414, a drug candidate containing Lactobacillus reuteri. The company was founded in 2013 and is headquartered in Stockholm, Sweden.